| nwamba # | Aha ngwaahịa | Nkọwa |
| CPD100587 | Phlorizin | Phlorizin, nke a na-akpọkwa phloridzin, bụ glucoside nke phloretin, dihydrochalcone, ezinụlọ nke bicyclic flavonoids, nke n'aka nke ya bụ otu n'ime ụzọ njikọ phenylpropanoid dị iche iche na osisi. Phlorizin bụ onye na-egbochi asọmpi nke SGLT1 na SGLT2 n'ihi na ọ na-asọ mpi D-glucose maka ijikọ onye na-ebu ya; Nke a na-ebelata ibugharị glucose gbasara akụrụ, na-ebelata oke glucose n'ọbara. A mụrụ Phlorizin dị ka ọgwụgwọ ọgwụ nwere ike ime maka ụdị ọrịa shuga 2, mana ejirila nhọrọ ndị ọzọ na-ekwe nkwa, dị ka canagliflozin na dapagliflozin dochie ya. |
| CPD0045 | Ipragliflozin | Ipragliflozin, nke a makwaara dị ka ASP1941, bụ onye na-egbochi SGLT2 dị ike ma họrọ maka ọgwụgwọ ụdị ọrịa shuga 2. Ọgwụgwọ Ipragliflozin na-eme ka njikwa glycemic dịkwuo mma mgbe agbakwunyere na ọgwụgwọ metformin ma nwee ike jikọta ya na mbelata ibu na mbelata ọbara mgbali elu ma e jiri ya tụnyere placebo. Ipragliflozin na-akwalite ọ bụghị naanị hyperglycemia kamakwa ọrịa shuga / oke ibu na-emetụta ọrịa metabolic na ụdị oke ọrịa shuga 2. A kwadoro ya maka ojiji na Japan na 2014 |
| CPD100585 | Tofogliflozin | Tofogliflozin, nke a makwaara dị ka CSG 452, bụ onye na-egbochi SGLT2 dị ike ma dị elu n'okpuru mmepe ọgwụgwọ ọrịa shuga mellitus. Tofogliflozin na-eme ka njikwa glycemic dịkwuo elu ma na-ebelata ibu ahụ n'ime ndị ọrịa nwere ụdị ọrịa shuga mellitus nke 2. Tofogliflozin na-egbochi ntinye glucose n'ime sel tubular na-adabere na ya. Mkpughe glucose dị elu (30?mM) maka awa 4 na 24 na-abawanye ụbara ọgbọ nrụgide oxidative na sel tubular, nke ọgwụgwọ tofogliflozin ma ọ bụ antioxidant N-acetylcysteine (NAC) kwụsịrị. |
| CPD100583 | Empagliflozin | Empagliflozin, nke a makwaara dị ka BI10773 (aha ahia Jardiance), bụ ọgwụ akwadoro maka ọgwụgwọ ụdị ọrịa shuga 2 na ndị okenye na 2014. Ọ bụ Boehringer Ingelheim na Eli Lilly na Company mepụtara ya. Empagliflozin bụ onye na-egbochi sodium glucose co-transporter-2 (SGLT-2), na-eme ka akụrụ na-amịkọrọ shuga dị n'ọbara wee kpochapụ na mmamịrị. Empagliflozin bụ onye na-egbochi sodium glucose co-transporter-2 (SGLT-2), nke a na-ahụ ihe fọrọ nke nta ka ọ bụrụ naanị n'ime tubules nso nke akụkụ nephronic na akụrụ. SGLT-2 bụ ihe dị ka pasent 90 nke nnabata glucose n'ọbara. |
| CPD100582 | Canagliflozin | Canagliflozin (INN, aha ahia Invokana) bụ ọgwụ maka ọgwụgwọ ụdị ọrịa shuga 2. Ọ bụ Mitsubishi Tanabe Pharma mepụtara ya ma na-ere ya n'okpuru ikike Janssen, ngalaba Johnson & Johnson. Canagliflozin bụ ihe mgbochi nke subtype 2 sodium-glucose transport protein (SGLT2), nke na-ahụ maka opekata mpe 90% nke nnabata glucose na akụrụ. Mgbochi onye na-ebufe a na-eme ka a na-ewepụ glucose ọbara site na mmamịrị. Na Machị 2013, canagliflozin ghọrọ onye na-egbochi SGLT2 izizi na United States. |
| CPD0003 | Dapagliflozin | Dapagliflozin, nke a makwaara dị ka BMS-512148, bụ ọgwụ eji agwọ ụdị ọrịa shuga 2 nke FDA kwadoro na 2012. Dapagliflozin na-egbochi subtype 2 nke protein sodium-glucose transport (SGLT2) nke na-ahụ maka opekata mpe 90% nke nnabata glucose na akụrụ. Mgbochi usoro mbufe a na-eme ka ewepụ glucose ọbara site na mmamịrị. N'ime ule ụlọ ọgwụ, dapagliflozin wedara HbA1c site na 0.6 na pasent placebo mgbe agbakwunyere metformin. |
